Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with Adriamycin by using a p53-independent pathway

被引:88
作者
Gartenhaus, RB [1 ]
Wang, P [1 ]
Hoffmann, P [1 ]
机构
[1] ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,DEPT PATHOL,DIV HEMATOL ONCOL,NEW HYDE PK,NY 11040
关键词
D O I
10.1073/pnas.93.1.265
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The WAF1/CIP1 protein has been identified as a downstream mediator of the tumor suppressor p53 in regulating cell cycle progression through a G(1)-phase checkpoint. Recent work has implicated the functional status of p53 as a critical determinant in the apoptotic response of certain cell lines to DNA damaging agents. By using human T-cell leukemia virus type I-transformed lymphoid cell lines that differ in their level and function of wild-type p53, we investigated the induction of WAF1/CIP1 and apoptosis after exposure to Adriamycin, a genotoxic agent. We found that regardless of the p53 status in these cell lines, WAF1/CIP1 RNA was rapidly induced in response to Adriamycin treatment. An elevated level of WAF1/CIP1 protein was observed as well. Additionally, we demonstrated that apoptosis was induced in all cell lines analyzed despite some having functionally inactive p53 protein. Our data suggest that a p53-independent pathway may play a role in the apoptotic response observed in some cell lines after exposure to DNA damaging agents.
引用
收藏
页码:265 / 268
页数:4
相关论文
共 24 条
  • [1] EXPRESSION OF ALTERNATIVELY SPLICED HUMAN T-LYMPHOTROPIC VIRUS TYPE-I PX MESSENGER-RNA IN INFECTED CELL-LINES AND IN PRIMARY UNCULTURED CELLS FROM PATIENTS WITH ADULT T-CELL LEUKEMIA LYMPHOMA AND HEALTHY CARRIERS
    BERNEMAN, ZN
    GARTENHAUS, RB
    REITZ, MS
    BLATTNER, WA
    MANNS, A
    HANCHARD, B
    IKEHARA, O
    GALLO, RC
    KLOTMAN, ME
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) : 3005 - 3009
  • [2] COLE SPC, 1986, CANCER CHEMOTH PHARM, V17, P259
  • [3] CHEMOTHERAPY FOR LARGE-CELL LYMPHOMA - OPTIMISM AND CAUTION
    COLEMAN, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (01) : 140 - 142
  • [4] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825
  • [5] FAN SJ, 1994, CANCER RES, V54, P5824
  • [6] COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA
    FISHER, RI
    GAYNOR, ER
    DAHLBERG, S
    OKEN, MM
    GROGAN, TM
    MIZE, EM
    GLICK, JH
    COLTMAN, CA
    MILLER, TP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) : 1002 - 1006
  • [7] GARTENHAUS RB, 1991, BLOOD, V78, P2956
  • [8] GARTENHAUS RB, 1996, IN PRESS LEUKEMIA
  • [9] IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION
    GAVRIELI, Y
    SHERMAN, Y
    BENSASSON, SA
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 119 (03) : 493 - 501
  • [10] A SELECTIVE PROCEDURE FOR DNA EXTRACTION FROM APOPTOTIC CELLS APPLICABLE FOR GEL-ELECTROPHORESIS AND FLOW-CYTOMETRY
    GONG, JP
    TRAGANOS, F
    DARZYNKIEWICZ, Z
    [J]. ANALYTICAL BIOCHEMISTRY, 1994, 218 (02) : 314 - 319